Actively Recruiting
Prospective Cohort Assessing the Prevalence and Progress of Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) in Chinese Subjects
Led by Humanity and Health Research Centre · Updated on 2025-03-24
20000
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a 10-year observational study focusing on patients with non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH), among Chinese subjects. This study aims to improve understanding of the causes, progression, diagnosis, treatment, and prevention of these liver conditions, which are linked to factors like obesity, high blood pressure, high cholesterol, and diabetes. It also seeks to clarify why some individuals develop NASH while others do not. The study involves collecting clinical data and biospecimens over a decade to support translational research on genetics and biomarkers related to NAFLD and NASH. It is a prospective cohort study without experimental treatments, focusing on tracking disease prevalence and progression through regular evaluations, including liver imaging and histology analyses. Participants will be monitored for up to 10 years, during which their liver condition and related health factors will be assessed through imaging, blood tests for biomarkers, and liver tissue analysis when applicable. The main outcome measured is the prevalence of NAFLD and NASH in the Chinese population. Safety monitoring and continued observation throughout the study will contribute to a comprehensive understanding of these liver diseases.
CONDITIONS
Brief Title
Longitudinal Observational Study Of Chinese With NAFLD/NASH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males or females aged 18 and older
- Adults being managed or treated for NAFL or NASH
- Able to communicate meaningfully with the Investigator and legally competent to provide written informed consent
You will not qualify if you...
- Incompetent to understand and/or sign the informed consent
- Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for females
- Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, and conditions associated with microvesicular steatosis
- Diagnosis of liver cirrhosis and/or hepatocellular carcinoma
- Diagnosis of chronic inflammatory disease other than NAFL/NASH, such as inflammatory bowel disease, rheumatoid arthritis, inflammatory lung disease, or severe infectious diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 10 years
Participants are observed over time to assess the prevalence and progression of NAFLD and NASH.
Trial Site Locations
Total: 1 location
1
Humanity and Health Medical Centre
Hong Kong, Hong Kong, 00852
Actively Recruiting
Research Team
Y
Yudong Wang, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here